Sodium-glucose cotransporter type 2 (SGLT2)

Sodium-glucose cotransporter type 2 (SGLT2) is an integral membrane protein predominantly expressed in the early proximal tubule of the kidney, encoded by the SLC5A2 gene. It is responsible for reabsorbing approximately 90% of filtered glucose from the renal tubular lumen. SGLT2 is the molecular target for several FDA-approved antidiabetic drugs (SGLT2 inhibitors or gliflozins), which reduce blood glucose independently of insulin by blocking renal glucose reabsorption and promoting glycosuria. Beyond glycemic control in type 2 diabetes, SGLT2 inhibition provides cardio- and renoprotective effects, and is increasingly recognized for benefits in chronic kidney disease and heart failure. SGLT2 expression is also implicated as a diagnostic and therapeutic biomarker in certain cancers, notably early lung adenocarcinoma[1][2][3][4][5][7].

Other names

Sodium-glucose transport protein 2Solute carrier family 5 member 2SLC5A2SGLT-2

Inhibition of glucose reabsorption in the proximal renal tubule, Increased urinary glucose excretion, Lowering of blood glucose, Cardioprotective and renoprotective mechanisms (multifactorial)